×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
HCM – hutchmed (china) limited - american depositary shares (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
HCM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/12
07:00 pm
hcm
HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)
Low
Report
HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)
12/11
11:00 pm
hcm
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy
Low
Report
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy
12/3
07:04 pm
hcm
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer [Yahoo! Finance]
Medium
Report
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer [Yahoo! Finance]
12/3
07:00 pm
hcm
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer
Low
Report
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer
12/3
07:00 pm
hcm
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer
Low
Report
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer
12/3
05:05 am
hcm
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer [Yahoo! Finance]
Low
Report
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer [Yahoo! Finance]
12/3
05:00 am
hcm
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer
Low
Report
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer
11/28
05:34 am
hcm
HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms [Yahoo! Finance]
Medium
Report
HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/13
06:06 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Dec 13
Low
Report
Form 6-K HUTCHMED (China) Ltd For: Dec 13
12/12
06:03 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Dec 12
Medium
Report
Form 6-K HUTCHMED (China) Ltd For: Dec 12
12/3
06:05 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Dec 03
Low
Report
Form 6-K HUTCHMED (China) Ltd For: Dec 03
11/29
06:04 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Nov 29
Low
Report
Form 6-K HUTCHMED (China) Ltd For: Nov 29
11/22
06:05 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Nov 22
Low
Report
Form 6-K HUTCHMED (China) Ltd For: Nov 22
11/20
06:04 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Nov 20
Low
Report
Form 6-K HUTCHMED (China) Ltd For: Nov 20
11/6
06:04 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Nov 06
Low
Report
Form 6-K HUTCHMED (China) Ltd For: Nov 06
10/31
06:05 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Oct 31
Medium
Report
Form 6-K HUTCHMED (China) Ltd For: Oct 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/3
Hutchison China MediTech Limited (HCM) Q4 2019 Earnings Call Transcript [The Motley Fool]
2.9%
1/13 Chi-Med Initiates a Phase II Trial of Surufatinib in Combination with Tuoyi in Patients with Advanced Solid Tumors 2.9%
10/23 HUTCHISON CHINA/S (NASDAQ: HCM) is now covered by analysts at Bank of America Corp. They set a "buy" rating on the stock. 3.1%
4/17 Chi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors 3.1%
7/30 Hutchison China MediTech Limited 2019 Q2 - Results - Earnings Call Slides [Seeking Alpha] 3.2%
2/6 Chi-Med Announces the Exercise of Underwriters’ Over-allotment Option for Public Offering of ADSs 3.8%
9/30 CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confirms its intention to hold Chi-Med as a strategic investment for the long term 4.9%
4/22 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.2%
10/11 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.0%
3/13 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. 10.3%
1/13 Chi-Med Initiates a Phase II Trial of Surufatinib in Combination with Tuoyi in Patients with Advanced Solid Tumors 2.9%
10/23 HUTCHISON CHINA/S (NASDAQ: HCM) is now covered by analysts at Bank of America Corp. They set a "buy" rating on the stock. 3.1%
4/17 Chi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors 3.1%
7/30 Hutchison China MediTech Limited 2019 Q2 - Results - Earnings Call Slides [Seeking Alpha] 3.2%
2/6 Chi-Med Announces the Exercise of Underwriters’ Over-allotment Option for Public Offering of ADSs 3.8%
9/30 CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confirms its intention to hold Chi-Med as a strategic investment for the long term 4.9%
4/22 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.2%
10/11 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.0%
3/13 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. 10.3%
TOP News Decliners
9/27
HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating.
-2.9%
6/14 Chi-Med Announces that Surufatinib Phase III SANET-ep Study Has Met its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early -2.7%
2/25 Chi-Med to announce 2019 Final Results on Tuesday, March 3, 2020 – adjustment to announcement and presentation logistics due to travel restrictions -3.3%
12/30 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -3.4%
9/3 Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma -5.3%
7/20 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -7.7%
1/23 Chi-Med Announces Pricing of US$110 Million Public Offering of ADSs -9.8%
1/21 Chi-Med Announces Proposed Public Offering of ADSs -12.6%
3/18 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -17.4%
6/27 Chi-Med Announces Secondary Offering of American Depositary Shares -18.8%
6/14 Chi-Med Announces that Surufatinib Phase III SANET-ep Study Has Met its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early -2.7%
2/25 Chi-Med to announce 2019 Final Results on Tuesday, March 3, 2020 – adjustment to announcement and presentation logistics due to travel restrictions -3.3%
12/30 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -3.4%
9/3 Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma -5.3%
7/20 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -7.7%
1/23 Chi-Med Announces Pricing of US$110 Million Public Offering of ADSs -9.8%
1/21 Chi-Med Announces Proposed Public Offering of ADSs -12.6%
3/18 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -17.4%
6/27 Chi-Med Announces Secondary Offering of American Depositary Shares -18.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: